C4 Imaging Announces Successful Completion of an Institutional Financing Round

C4 Imaging LLC, an early-stage medical device company, has completed its latest round of financing, which included a significant institutional component. Institutional investment was led by Stoneworth Financial, LLC, a Houston based investment banking group. Proceeds will be used for growth capital, targeted at accelerating clinical adoption of C4 Imaging’s portfolio of FDA cleared products developed around its unique encapsulated positive-signal MRI technology. In addition, funds will be used to complete the development of a new generation of medical devices designed to improve MRI utilization in the breast biopsy market.

“With the recent FDA 510(k) clearance of Nova, our multimodality fiducial marker, these funds position us to maximize our growth opportunities,” said Andrew Bright, C4 Imaging’s President and CEO. “We’re excited that a group of sophisticated investors led by Stoneworth Financial have recognized the significant potential in our product portfolio, as well as in our plans to launch C4 based positive MRI signal products specifically designed for the breast cancer biopsy market.”

Stoneworth Principal Evan Betzer commented, "Our assessment of C4 Imaging’s technology and its market opportunities, in both radiation oncology and breast cancer, made for a compelling investment case. We’re pleased to partner with C4 Imaging and ensure that we are an excellent resource for the C4 team.”